DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Patent 6,515,117 protects QTERNMET XR, XIGDUO XR, FARXIGA, QTERN, BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in six NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and thirteen patent family members in forty-one countries.
Summary for Patent: 6,515,117
|Title:||C-aryl glucoside SGLT2 inhibitors and method|
|Abstract:||An SGLT2 inhibiting compound is provided having the formula ##STR1## A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.|
|Inventor(s):||Ellsworth; Bruce (Princeton, NJ), Washburn; William N. (Titusville, NJ), Sher; Philip M. (Plainsboro, NJ), Wu; Gang (Princeton, NJ), Meng; Wei (Pennington, NJ)|
|Assignee:||Bristol-Myers Squibb Company (Princeton, NJ)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 6,515,117|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Argentina||026024||⤷ Free Forever Trial|
|Argentina||040032||⤷ Free Forever Trial|
|Austria||295848||⤷ Free Forever Trial|
|Austria||353334||⤷ Free Forever Trial|
|Australia||2003237886||⤷ Free Forever Trial|
|Australia||781009||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|